secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axogen, Inc. (AXGN)
CIK:        0000805928
Form:       8-K
Filed at:   2026-10-01T21:25:33+00:00
Accession:  0000805928-26-000104
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Axogen closes BioCircuit acquisition, adding FDA-cleared NerveTape; sees ~$34M 2027 revenue contribution
--------------------------------------------------------------------------------

- Axogen completed its acquisition of privately held BioCircuit Technologies, Inc. on October 1, 2026, adding NerveTape, described as the first FDA-cleared device for sutureless peripheral nerve repair.
- BioCircuit expected to contribute approximately $6 million to Q4 2026 revenue and approximately $34 million to 2027 revenue.
- That contribution was not included in Axogen's most recently issued full-year 2026 guidance of at least 24% revenue growth.
- Company continues to expect full-year 2026 gross margin of at least 73% and to be free cash flow positive.
- CEO Michael Dale said NerveTape is 'simpler, faster, and more effective than microsuturing' and fits Axogen's direct sales and hospital contracting; purchase price not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000104/0000805928-26-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/805928/000080592826000104/axgn-20261001.htm
  HTML page:      https://secwatch.observer/filing/0000805928-26-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer